A super-trail molecule comprising two trail trimers
US-2024254193-A1 · Aug 1, 2024 · US
NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)
NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525) · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C07K14/70575 |
| Official title | {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)} |
| Display label | NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525) |
| Total patents | 723 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is declining.
| Year | Patents |
|---|---|
| 2015 | 35 |
| 2016 | 27 |
| 2017 | 53 |
| 2018 | 61 |
| 2019 | 72 |
| 2020 | 82 |
| 2021 | 87 |
| 2022 | 80 |
| 2023 | 71 |
| 2024 | 72 |
| 2025 | 64 |
| 2026 | 19 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
US-2024139243-A1 · May 2, 2024 · US
CSGP4 - Specific Chimeric Antigen Receptor for Cancer
US-2016376375-A1 · Dec 29, 2016 · US
Fusion proteins for modulating regulatory and effector t cells
US-2016347846-A1 · Dec 1, 2016 · US
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US-2016340430-A1 · Nov 24, 2016 · US
Enhanced antigen presenting ability of rna car t cells by co-introduction of costimulatory molecules
US-2016340406-A1 · Nov 24, 2016 · US
Chimeric antigen receptor compositions
US-2016333114-A1 · Nov 17, 2016 · US
Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
US-2016319027-A1 · Nov 3, 2016 · US
Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
US-2016303174-A1 · Oct 20, 2016 · US
Methods for treating cancer
US-2016297865-A1 · Oct 13, 2016 · US
Human leucine zipper/trail recombinant polypeptides
US-2016280761-A1 · Sep 29, 2016 · US
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US-9441044-B2 · Sep 13, 2016 · US
Tnfrsf-binding agents and uses thereof
US-2016256527-A1 · Sep 8, 2016 · US
Chimeric antigen receptor
US-2016237139-A1 · Aug 18, 2016 · US
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
US-2016200819-A1 · Jul 14, 2016 · US
Chimeric antigen receptor and methods of use thereof
US-2016185862-A1 · Jun 30, 2016 · US
Protein Production Method
US-2016122427-A1 · May 5, 2016 · US
Neutralization of cd95 activity blocks invasion of glioblastoma cells in vivo
US-2016115236-A1 · Apr 28, 2016 · US
Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
US-9309320-B2 · Apr 12, 2016 · US
Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
US-9266960-B2 · Feb 23, 2016 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C07K14/70575?
- CPC C07K14/70575 is the Cooperative Patent Classification code for “NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525).”
- How many patents are filed under CPC C07K14/70575 (NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525))?
- Our database includes 723 publications tagged with this CPC code.
- Is patent activity under CPC C07K14/70575 growing?
- Publication counts under this code: 72 in 2024 vs 64 in 2025 (latest complete years).